▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3293 by analyst upside · 2026-09-27
USPH
U.S. Physical Therapy, Inc.
Healthcare · Market Cap $1B · P/E 471.3x
ANALYST PRICE TARGET
+14.3%
implied upside to consensus target
Current Price $84.84
Consensus Target $97.0
Bull Target $100.0
Bear Target $95.0
Analysts Covering 6
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
2
Hold
1
Sell
0
52-Week Low $58.19
52-Week High $93.5
YTD Return +9.6%
FUNDAMENTALS
Market Cap $1B
P/E Ratio (TTM) 471.3x
Forward P/E 25.3x
EPS (TTM) $0.18
PEG Ratio 2.78
Dividend Yield 2.17%
Revenue (TTM) $804M
Profit Margin 4.0%
52-WEEK RANGE
52-Week Low $58.19
52-Week High $93.5
Current Price $84.84
Bear Target $95.0
Bull Target $100.0
● Now $84.84 ● Target $97.0
TRADING DATA
Avg Volume 212K
YTD Return +9.6%
Analyst Count 6
Consensus Buy
Upside to Target +14.3%
Last Updated 2026-09-27

ANALYST SUMMARY

U.S. Physical Therapy, Inc. (USPH) is currently trading at $84.84 with a Wall Street consensus price target of $97.0, implying potential upside of 14.3% over the next 12 months. 6 analysts currently cover USPH, with a consensus rating of Buy - 83% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $100.0, while the most cautious has a target of $95.0.

USPH operates in the Healthcare sector with a market capitalisation of $1B. The stock is up 9.6% year-to-date and is currently trading near the upper end of its 52-week range of $58.19 – $93.5.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

STAA +33.6%
STAAR Surgical Company
$1B · P/E 256.4x · Hold
RGEN -0.1%
Repligen Corporation
$11B · P/E 263.4x · Buy
ICLR +7.5%
ICON Public Limited Company
$13B · P/E 265.1x · Buy
CORT +21.4%
Corcept Therapeutics Incorporated
$13B · P/E 258.0x · Buy
ATRC -8.6%
AtriCure, Inc.
$3B · P/E 278.0x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for USPH, with each firm's 90-day track record across all stocks we track. See full firm rankings →

JP Morgan - Reiterated
Overweight → Overweight 2026-09-11 43% win rate (7 calls)
Barrington Research - Reiterated
Outperform → Outperform 2026-08-10 Building track record
Citizens reit
Market Outperform → Market Outperform 2026-06-24 Building track record
Barrington Research - Reiterated
Outperform → Outperform 2026-05-13 Building track record
Citizens - Reiterated
Market Outperform → Market Outperform 2026-05-08 Building track record
Barrington Research - Reiterated
Outperform → Outperform 2026-02-20 Building track record
Barrington Research - Reiterated
Outperform → Outperform 2026-01-05 Building track record
JP Morgan - Reiterated
Overweight → Overweight 2025-11-24 43% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
66
out of 100
Coverage depth
15/30
Consensus clarity
29/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →